Ripretinib
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alen Antony Pathil, M.D.[2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Ripretinib is a kinase inhibitor that is FDA approved for the treatment of Gastrointestinal stromal tumor in adults who have been already treated with # or more kinase inhibitors, including imatinib.. Common adverse reactions include alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia, and vomiting.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Ripretinib FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
The recommended dosage of ripretinib is 150 mg orally once daily with or without food until disease progression or unacceptable toxicity.
The tablet is swallowed as whole and should be taken on the same time each day. The patients are also advised to take the missed dose earliest if the missed dose is less than 8hrs, and advised to not take additional doses if they develop vomiting.
If they develop any adverse effects, reduce the dosage to 100 mg once daily. However, if they can't tolerate 100 mg, it should be completely discontinued.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Ripretinib FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
There is limited information regarding Ripretinib Contraindications in the drug label.
Warnings
There is limited information regarding Ripretinib Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Ripretinib Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Ripretinib Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Ripretinib Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Ripretinib in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ripretinib in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Ripretinib during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Ripretinib in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Ripretinib in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Ripretinib in geriatric settings.
Gender
There is no FDA guidance on the use of Ripretinib with respect to specific gender populations.
Race
There is no FDA guidance on the use of Ripretinib with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Ripretinib in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Ripretinib in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Ripretinib in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Ripretinib in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Ripretinib Administration in the drug label.
Monitoring
There is limited information regarding Ripretinib Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Ripretinib and IV administrations.
Overdosage
There is limited information regarding Ripretinib overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Ripretinib Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Ripretinib Mechanism of Action in the drug label.
Structure
There is limited information regarding Ripretinib Structure in the drug label.
Pharmacodynamics
There is limited information regarding Ripretinib Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Ripretinib Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Ripretinib Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Ripretinib Clinical Studies in the drug label.
How Supplied
There is limited information regarding Ripretinib How Supplied in the drug label.
Storage
There is limited information regarding Ripretinib Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Ripretinib |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Ripretinib |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Ripretinib Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Ripretinib interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Ripretinib Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Ripretinib Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.